<DOC>
	<DOCNO>NCT02163824</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety KPI-121 ophthalmic suspension compare placebo subject undergone cataract surgery . The efficacy safety two different concentration two different dose regimen KPI-121 also assess .</brief_summary>
	<brief_title>Safety Efficacy KPI-121 Subjects With Postsurgical Inflammation</brief_title>
	<detailed_description>This Phase III , multicenter , double-masked , randomize , placebo-controlled , parallel-group study design evaluate efficacy safety two dos two dose regimen KPI-121 ophthalmic suspension versus placebo subject require treatment postoperative anterior ocular inflammation . Approximately 500 subject screen 402 subject one study eye randomize study approximately 25 center locate United States . Subjects experience postoperative inflammation first day follow routine , uncomplicated , cataract surgery meet eligibility criterion randomize one four study group ( 0.25 % four time daily 1.0 % two time daily ) Placebo A four time daily Placebo B two time daily . Drug product placebo initiate day follow surgery instill one two drop study eye accord assign dose regimen 14 day . This study include 7 clinic visit ( include surgery day ) 18 33 day total study duration . Visit 1 ( Screening ) occur 14 1 day ( ) prior surgery , subject meet preoperative screen inclusion/exclusion criterion enter study . At Visit 2 ( Surgery/Day 0 ) subject undergo routine cataract surgery accord Investigator 's normal procedure . Visit 3 ( Randomization/Day 1 ) occur day follow surgery . Following randomization , subject instruct return clinic evaluate Visit 4 ( Day 3 +2 day ) , Visit 5 ( Day 8 ±1 day ) , Visit 6 ( Day 15 ±1 day ) . The last dose study product administer upon completion 14 day evaluation . Following End Study Product Use Visit ( Visit 6 ; Day 15 ±1 day ) , subject ask return clinic Day 17-19 Visit 7 ( Follow-Up ) release study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Eye Infections</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>FURTHER STUDY DETAILS PROVIDED BY KALA PHARMACEUTICALS , INC . Candidates routine , uncomplicated cataract surgery In Investigator 's opinion , potential postoperative Snellen Distance VA pinhole method least 20/200 study eye . Known hypersensitivity/contraindication study product ( ) component . History glaucoma , IOP &gt; 21 mmHg screen randomization visit , treat glaucoma either eye . Diagnosis : ongoing ocular infection ; severe/serious ocular condition judgment Investigator could confound study assessment limit compliance ; severe/serious systemic disease uncontrolled medical condition judgment Investigator could confound study assessment limit compliance ; expose investigational drug within 30 day prior screen 19 day follow surgery . In opinion Investigator study coordinator , unwilling unable comply study protocol unable successfully instill eye drop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>postsurgical</keyword>
	<keyword>postoperative</keyword>
	<keyword>ocular</keyword>
	<keyword>cataract</keyword>
	<keyword>inflammation</keyword>
	<keyword>pain</keyword>
	<keyword>corticosteroid</keyword>
</DOC>